4 hours Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns “Buy” Rating from HC Wainwright MarketBeat
HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Friday.
Nasdaq 100 · Pharmaceuticals · Science